Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce. After ...
Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback